Şule Çalışkan Kamış

Prof. Şule Çalışkan Kamış

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
MÇMetin çil
Metin çil
BYBegül Yağcı
Begül Yağcı
Introduction and importance: Dyskeratosis congenita (DC) is a rare multisystem disorder primarily characterized by bone marrow failure due to telomere shortening. Typical clinical features include oral leukoplakia, skin hyperpigmentation, and nail dystrophy, along with an increased risk of malignancies. Hoyeraal–Hreidarsson syndrome (HH), a severe variant of DC, is associated with profound neurological and immunological complications, emphasizing the importance of early diagnosis and genetic evaluation to guide appropriate management. Case presentation: The authors present a case of a 2-year-old girl diagnosed with Hoyeraal–Hreidarsson syndrome, linked to a newly discovered mutation in the poly (A)-specific ribonuclease (PARN) gene. The patient exhibited intrauterine growth retardation (IUGR), congenital cytomegalovirus (CMV) infection, immunodeficiency, microcephaly, and cerebellar hypoplasia. Whole-exome sequencing (WES) identified a novel mutation in the PARN gene. Clinical discussion: Hoyeraal–Hreidarsson syndrome, a severe form of DC, manifests with multisystem involvement and is genetically heterogeneous. Early genetic testing through techniques such as WES can aid in diagnosing rare syndromes like HH and guide treatment strategies, including bone marrow transplantation. Conclusion: This case underscores the importance of genetic evaluation in complex, rare syndromes like HH. Whole-exome sequencing plays a crucial role in identifying pathogenic mutations and tailoring management. The patient’s prognosis is being closely monitored following bone marrow transplantation.

30 June 2021 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
BYBegül Yağcı
Begül Yağcı
Purpose: In this study, it was aimed to evaluate the clinical, radiological and genetic features of children who were followed up with the diagnosis of Neurofibromatosis type 1 (NF-1). Materials and Methods: Patients who were 0-18 years diagnosed with Neurofibromatosis according to National Institute of Health 1988 criteria between September 2012 and September 2019 were included in the study. Patient data were collected through patient files and hospital information system. Results: A total of 50 patients were included in the study. The male/female ratio was 0.92. The median age at the time of diagnosis was 5.6 years (age range: 1-18 years). The most common finding was cafe-au-lait spots detected in all patients. Family history was found in 60% of the patients and consanguinity between parents in 14%. Neurofibroma was detected in 12%, Lisch nodule in 36% of the patients. Axillary freckling ratio was 82%, inguinal freckling ratio was 78%. Tumors were found in 22% of the patients, optic glioma in 12%, and plexiform neurofibroma in 6%. Focal areas of signal intensity (FASI) was found 56% in cranial magnetic resonance imaging (MRI). Conclusion: The relationship between mutation type and clinical and radiological features in NF-1 was evaluated. There was no statistically significant difference in clinical and radiological findings between patients with or without mutation. Large-scale studies are needed to reveal the factors that determine the clinical phenotype in patients with NF-1 diagnosis.

6 November 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
BYBegül Yağcı
Begül Yağcı
Introduction: Pediatric lymphadenopathy is common and usually benign, yet selecting children who need biopsy remains challenging. We evaluated clinical and ultrasonographic (US) predictors of malignancy in a large pediatric cohort. Methods: We retrospectively analyzed 500 children (0-18 years) evaluated for regional lymphadenopathy at a tertiary pediatric hematology-oncology clinic (June 2024-March 2025). Demographics, node location/size/count, US features, viral tests, and biopsy/bone-marrow results were extracted. Univariable tests and multivariable logistic regression identified independent predictors of malignancy. Model performance was assessed with Hosmer-Lemeshow and ROC AUC. Results: Median age was 6 years; cervical nodes predominated (92.2%), and multiple nodes were frequent (93.6%). Biopsy was performed in 47 children; malignancy was found in 23. Final diagnoses in the cohort were reactive (87.4%), infectious (6.8%), hematologic malignancy (4.4%), and solid tumor metastasis (1.4%). On univariable analysis, node size ≥2 cm, multiplicity, and region were associated with malignancy ( p < 0.05). In multivariable analysis, only US assessment remained independently predictive: nodes categorized as suspicious on US had ∼56-fold higher odds of malignancy (adjusted OR ≈ 55.6; 95% CI 14.3-200; p < 0.001), whereas size and region were not significant. The model showed good calibration and excellent discrimination (AUC = 0.92; 95% CI 0.88-0.96). Discussion: US features outperformed traditional parameters (size/site) for predicting malignancy. Incorporating US-driven criteria into pathways may reduce unnecessary biopsies while preserving timely cancer detection.

14 August 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
BYBegül Yağcı
Begül Yağcı
Background: Alveolar soft part sarcoma (ASPS) is an extremely rare soft tissue sarcoma, accounting for less than 1% of all soft tissue sarcomas. Approximately 5%–10% of ASPS cases occur in children and adolescents. Despite its indolent local course, its high metastatic potential necessitates comprehensive, multidisciplinary management.Case presentation: We present a pediatric patient diagnosed with metastatic ASPS originating from the left thigh. Initial management included wide local excision and adjuvant radiotherapy. Immunohistochemistry demonstrated strong nuclear TFE3 positivity, supporting the diagnosis. Although FISH analysis for ASPSCR1–TFE3 fusion was planned, technical limitations prevented archival imaging. Despite initial local control, the patient developed pulmonary, hepatic, brain, and intraabdominal metastases during follow-up. Serial imaging, including 18F-FDG PET/CT and brain MRI, revealed progressive disease with increasing metastatic burden in the lungs, mediastinum, brain, and distal colon. The patient underwent multiple systemic treatments over approximately 30 months, including tyrosine kinase inhibitors, an mTOR inhibitor (sirolimus), and immune checkpoint inhibition (pembrolizumab), alongside multiple courses of radiotherapy. The entire treatment timeline illustrates the complex, multidisciplinary management required for this ultra-rare malignancy.Conclusion: This case highlights the critical role of histopathological and molecular confirmation, multidisciplinary care, and emerging targeted and immunotherapy approaches in pediatric ASPS. Collaborative multicenter trials are urgently needed to establish evidence-based treatment strategies for this challenging disease.

4 March 2025 in Scientific Reports
Verified
Journal Article
Open access
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
BYBegül Yağcı
Begül Yağcı
AKAyşe Selcan Koç
Ayşe Selcan Koç
MÇMetin Çil
Metin Çil
Acute lymphoblastic leukemia (ALL) and other hematological malignancies are the most common cancers in children, with chemotherapy and/or radiotherapy as the primary treatment options. These treatments, however, may have long-term effects on ovarian function and fertility in female survivors. This study aims to evaluate ovarian function and reserve in female survivors of childhood hematological malignancies by assessing hormonal markers and ovarian follicle count. This cross-sectional study included 30 female survivors of acute leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) who completed chemotherapy between 2013 and 2023. Hormonal markers including anti-Müllerian hormone (AMH), inhibin B, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and ovarian follicle counts were measured. Statistical analysis was performed using SPSS, with a significance level of p < 0.05. Out of 263 patients diagnosed with hematological malignancies during the study period, 30 female patients were included. The median age at diagnosis was 14 years (range: 7-24 years). The malignancy breakdown was as follows: 7 patients (23.3%) with ALL, 2 patients (6.7%) with acute myeloid leukemia (AML), 9 patients (30%) with HL, and 12 patients (40%) with NHL. The median number of right ovarian follicles was 6 (range: 0-13), and the median number of left ovarian follicles was 7 (range: 2-12), with a total median follicle count of 12.5 (range: 5-25). AMH levels were normal in 26 patients (86.7%) and low in 3 patients (10%), with 3 patients (10%) diagnosed with decreased ovarian reserve (DOR), defined by AMH levels < 0.96 ng/mL. Inhibin-B levels were normal in 25 patients (83.3%), elevated in 1 patient (3.3%), and low in 4 patients (13.3%). Significant correlations were found between AMH and inhibin-B (p = 0.005, r = 0.508), FSH and inhibin-B (p = 0.041, r = 0.375), and inhibin-B and total follicle count (p = 0.014, r = 0.444). Additionally, a significant modarate correlation between AMH levels and total follicle count was observed (p = 0.033, r = 0.396). The evaluation of ovarian reserve using AMH, inhibin B, and ovarian follicle counts provides critical insights for fertility planning in survivors of childhood cancer. Early and comprehensive assessments may improve reproductive outcomes and quality of life for these patients.

23 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Şule Çalışkan KamışŞule Çalışkan Kamış
Şule Çalışkan Kamış
MÇMetin çil
Metin çil
BYBegül Yağcı
Begül Yağcı
Background/Objective: Tumor biomarkers are widely used in adult oncology, but their diagnostic value in pediatric patients remains unclear. This study aimed to evaluate the clinical significance of CA-125, CA 19-9, CA 15-3, and CEA in children evaluated for suspected malignancy. Methods: This retrospective study included 211 pediatric patients (0–18 years) referred to a tertiary pediatric oncology center. Serum levels of the four biomarkers were analyzed in relation to patient demographics, imaging findings, and final diagnoses. Statistical analyses included chi-square, Mann–Whitney U, Kolmogorov–Smirnov tests, and receiver operating characteristic (ROC) curve analysis. Results: Of the 211 patients, 35 (16.6%) were diagnosed with malignancy. Elevated CA-125 was significantly associated with malignancy (p = 0.002), particularly among postpubertal female patients. Imaging abnormalities were more frequent in CA-125–positive cases (p < 0.001) and in patients with confirmed malignancy. ROC curve analysis demonstrated that CA-125 had an area under the curve (AUC) of 0.642, indicating modest discriminatory power. No significant associations were found for CA 19-9, CA 15-3, or CEA. Conclusions: CA-125 may serve as an adjunctive diagnostic biomarker in pediatric oncology, particularly in postpubertal girls and when interpreted alongside imaging findings. Other markers showed limited diagnostic value. Given its low sensitivity, CA-125 is not suitable as a standalone screening test in children. Larger, multicenter prospective studies are needed to establish pediatric-specific reference ranges and validate these findings.